Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: A 4-week open-label, parallel-group study of major depressive disorder

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 781-786

  Nagao, Kei ^a,b   Kishi, Taro ^a   Moriwaki, Masatsugu ^a   Fujita, Kiyoshi ^c,d   Hirano, Shigeki ^e   Yamanouchi, Yoshio ^a   Funahashi, Toshihiko ^b   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Jindai Hospital   (Japan)

^c Okehazama Hospital   (Japan)

^d Neuroscience Research Center   (Japan)

^e TOYOTA MEMORIAL HOSPITAL   (Japan)

Author keywords

Duloxetine; Major depressive disorder; Mirtazapine

Indexed keywords

DULOXETINE; MIRTAZAPINE;

ADULT; ARTICLE; BEDTIME DOSAGE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; JAPAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA;

EID: 84878746810     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S43600     Document Type: Article

References (9)

1. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427-452.
2. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;12:CD006528.
3. Gartlehner G, Thaler K, Hansen RA, Gaynes BN. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. Drug Saf. 2009;32(12): 1159-1173.
4. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.
5. Cookson J, Gilaberte I, Desaiah D, Kajdasz DK. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol. 2006;21(5):267-273.
6. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
7. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
8. Kishi T, Kitajima T, Ikeda M, et al. CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. Neuromolecular Med. 2009;11(2):53-57.
9. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.